If you're looking for ASX 200 dividend shares to buy, then you may want to check out the two listed below.
Both have recently been named as buys by analysts. Here's why they rate them highly:
Image source: Getty Images
Macquarie Group Ltd (ASX: MQG)
The first ASX 200 dividend share that could be in the buy zone is investment bank Macquarie.
The team at Morgans is very positive on Macquarie and has an add rating and $215.00 price target on the company's shares.
The broker likes Macquarie due to its exposure to long-term structural growth areas such as infrastructure and renewables. It also expects the bank to benefit from recent market volatility through its trading businesses and gain market share in Australian mortgages.
In respect to dividends, the broker is expecting partially franked dividends of $7.07 per share in FY 2023 and $7.47 per share in FY 2024. Based on the current Macquarie share price of $174.45, this will mean yields of 4.1% and 4.3%, respectively.
Medibank Private Ltd (ASX: MPL)
Another ASX 200 dividend share that has been named as a buy is private health insurer Medibank.
A recent note out of Citi reveals that its analysts have a buy rating and $4.00 price target on the company's shares.
Citi was pleased with Medibank's performance in FY 2022. It highlights the very strong showing from its private health insurance business and notes that the company's FY 2023 performance should be supported by higher interest rates.
Overall, the broker is expecting this to lead to its shares providing investors with attractive dividend yields in the coming years. For example, Citi is forecasting fully franked dividends of 15.9 cents per share in FY 2023 and 16.3 cents per share in FY 2024. Based on the current Medibank share price of $3.65, this will mean yields of 4.35% and 4.5%, respectively.
